Table 1.
Baseline characteristics of the study population
| History of childhood resolved pancreatitis | No history of childhood pancreatic disease | P value | |
|---|---|---|---|
| Number | 281 | 1,801,716 | |
| Age, years | 17.5 ± 0.6 | 17.4 ± 0.4 | <0.001 |
| Male, number (%) | 195 (69.4) | 1,043,796 (57.9) | <0.001 |
| Female, number (%) | 86 (30.6) | 757,920 (42.1) | |
| Male height, cm | 174.7 ± 6.6 | 174.0 ± 6.8 | 0.143 |
| Female height, cm | 162.6 ± 6.6 | 162.3 ± 6.1 | 0.593 |
| Male BMI, kg/m2 | 21.9 ± 3.7 | 21.6 ± 3.4 | 0.224 |
| Female BMI, kg/m2 | 22.4 ± 4.3 | 21.7 ± 3.4 | 0.092 |
| BMI categories, number (%)† | 0.002 | ||
| Underweight | 24 (8.5) | 123,829 (6.9) | |
| Normal weight | 204 (72.6) | 1,451,498 (80.6) | |
| Overweight and obese | 53 (18.9) | 226,389 (12.6) | |
| Completed high school education, % | 87 | 83 | 0.071 |
| Residential socioeconomic status, % | 0.533 | ||
| Low | 23 | 26 | |
| High | 23 | 22 | |
| Cognitive performance level, % | 0.115 | ||
| Low | 15 | 16 | |
| Medium | 67 | 71 | |
| High | 18 | 14 | |
| Country of origin, % | <0.001 | ||
| Israel | 7 | 7 | |
| Former USSR | 28 | 16 | |
| Asia | 23 | 24 | |
| Africa | 19 | 23 | |
| Europe | 23 | 28 | |
| Ethiopia | 1 | 1 | |
| Period of enrollment, number (%) | 0.001 | ||
| 1979–1988 | 50 (17.8) | 452,032 (25.1) | |
| 1989–1998 | 94 (33.5) | 653,227 (36.3) | |
| 1999–2008 | 137 (48.8) | 696,457 (38.7) | |
| Unimpaired health, %‡ | 78 | 81 | 0.71 |
| Duration of follow-up, years§ | 20.0 ± 7.8 | 21.6 ± 8.2 | 0.001 |
| Age at end of follow-up, years§ | 37.5 ± 7.9 | 38.9 ± 8.3 | 0.004 |
Data are means ± SD unless otherwise indicated. USSR, Union of Soviet Socialist Republics.
†
BMI categories classified according to percentiles: underweight (<5th), normal BMI (≥5th to <85th), and overweight and obese (≥85th). BMI percentiles determined by the U.S. Centers for Disease Control and Prevention sex- and age-specific BMI range.
‡
Unimpaired health was defined as lack of chronically prescribed medical treatment and absence of a history of any major disease or a history of a major operation.
§
Follow-up extended from initial medical assessment until 31 December 2016.